Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons
Dinutuximab beta significantly prolonged OS compared to historical control cohorts not treated with dB in both unadjusted and adjusted indirect comparisons.
Authors
- R. Ladenstein
- Holger N. Lode (ORCID: https://orcid.org/0000-0002-1201-208X)
- Nikolai Siebert (ORCID: https://orcid.org/0000-0001-6254-1302)
- Juliet C. Gray (ORCID: https://orcid.org/0000-0002-5652-4722)
- Aleksandra Wieczorek (ORCID: https://orcid.org/0000-0001-6750-2628)
- Przemysław Holko (ORCID: https://orcid.org/0000-0002-6821-4078)
- Isaac Yaniv (ORCID: https://orcid.org/0009-0005-1063-5872)
- Carla Manzitti (ORCID: https://orcid.org/0000-0002-1501-5518)
- P Kawalec
- Katarzyna Śladowska (ORCID: https://orcid.org/0000-0002-6633-0999)
- Lucas Moreno
- Adela Cañete
- Sascha Troschke-Meurer
- Shifra Ash
- Alberto Garaventa
- Genevieve Laureys
- Dominique Valteau-Couanet
- Cormac Owens
- John Anderson
Institutions
- Université Paris-Sud (FR)
- Hebron University (PS)
- Jagiellonian University (PL)
- Universitätsmedizin Greifswald (DE)
- Great Ormond Street Hospital (GB)
- Ghent University Hospital (BE)
- Istituto Giannina Gaslini (IT)
- Institut Gustave Roussy (FR)
- Hospital Universitari i Politècnic La Fe (ES)
- Schneider Children's Medical Center (IL)
- Rappaport Family Institute for Research in the Medical Sciences (IL)
- St Anna Children's Hospital (AT)
- Vall d'Hebron Hospital Universitari (ES)
- Our Lady's Hospital (IE)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- University of Southampton (GB)
- University College London (GB)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-22
- DOI
- https://doi.org/10.3389/fonc.2025.1736165
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Recordati Rare Diseases
- Deutsche Forschungsgemeinschaft
- Ministero della Salute